Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success

Date: January 1, 2012
Pages: 152
Price:
US$ 3,500.00
License [?]:
Publisher: GBI Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E6864CEAAA5EN
Leaflet:

Download PDF Leaflet

Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success” which provides an insight into the different endpoints that are used in cardiovascular clinical trials. The report examines various aspects of clinical trial endpoints in cardiovascular disorders, such as analysis of the major marketed cardiovascular drugs, with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, the most promising cardiovascular drugs in the therapeutic pipeline with details on safety, efficacy and clinical trials, and terminated trial analysis. The report also includes company profiles that highlight the cardiovascular drugs of different companies.

Cardiovascular disorders represent a collective group of disorders that affect the functioning of the heart and the blood vessels. These disorders are one the most prevalent groups of disorders in the world today, and represent a significant proportion of the world’s total diseased population. Most of them cause significant morbidity and disability.

The global cardiovascular therapeutics market was valued at $93.5 billion in 2010 and expected to reach revenues of $115.6 billion by 2017 with a CAGR of 3.1%. Approximately 127 million patients received pharmacological treatment for their cardiovascular diseases in 2011 with average cost of therapy being $596 per year. In addition, the average annual cost of therapy for the cardiovascular diseases therapeutic area appears likely to increase at a gradual rate over the next one to two years, with an expected price decline in 2011 onwards.

This report details the endpoints in clinical trials for cardiovascular disorders, highlighting the five major cardiovascular disorders, which are atherosclerosis, atrial fibrillation, dyslipidemia, hypertension and venous thromboembolism. The classification of five major cardiovascular diseases is done on the basis of the number of pipeline molecules present in Phase III of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, such as those related to the effectiveness of treatment as well as other factors. However, endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be important to the objective of the study and represent the most effective way to assess pharmacological response.

Scope
  • Data and analysis on the marketed products and analysis of their efficacy and safety details.
  • Analysis of the five major cardiovascular diseases which include atherosclerosis, atrial fibrillation, dyslipidemia, hypertension and venous thromboembolism.
  • Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
  • Analysis on most promising molecules of five major cardiovascular diseases with emphasis on their efficacy and safety details.
  • Company profiling talks in detail about the companies, which are strong in the market.
Reasons to buy
  • Understand the trends in clinical trial endpoints used for cardiovascular diseases
  • Build effective strategies to launch their pipeline products by identifying the right endpoints
  • Understand and apply surrogate endpoints and clinical biomarkers as endpoints for cardiovascular diseases
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 ENDPOINTS - CLINICAL TRIALS IN CARDIOVASCULAR DISORDERS - OVERVIEW

2.1 Introduction
2.2 Types of Endpoints
  2.2.1 Primary Endpoints
  2.2.2 Secondary Endpoints
2.3 GBI Research Report Guidance

3 ENDPOINTS - CLINICAL TRIALS IN CARDIOVASCULAR DISORDERS - MAJOR ENDPOINTS OF TOP FIVE CARDIOVASCULAR DISORDERS

3.1 Endpoints - Major Marketed Drugs of Top Five Cardiovascular Disorders and their Regulatory Approval
  3.1.1 Atherosclerosis
  3.1.2 Atrial Fibrillation
  3.1.3 Dyslipidemia
  3.1.4 Hypertension
  3.1.5 Venous Thromboembolism

4 ENDPOINTS - CLINICAL TRIALS IN CARDIOVASCULAR DISORDERS - MARKETED AND PIPELINE PRODUCT ASSESSMENT

4.1 Atherosclerosis
  4.1.1 Primary Endpoints Used in Atherosclerosis Clinical Trials
  4.1.2 Secondary Endpoints Used in Atherosclerosis Clinical Trials
  4.1.3 Major Marketed Drugs - Safety and Efficacy Analysis
  4.1.4 Phase III Clinical Trial Analysis
  4.1.5 Most Promising Drug’s Profile
  4.1.6 Phase II Clinical Trial Analysis
  4.1.7 Terminated Trials Analysis
4.2 Atrial Fibrillation
  4.2.1 Primary Endpoints Used in Atrial Fibrillation
  4.2.2 Secondary Endpoints Used in Atrial Fibrillation
  4.2.3 Major Marketed Drugs - Safety and Efficacy Analysis
  4.2.4 Phase III Clinical Trial Analysis
  4.2.5 Most Promising Drug’s Profile
  4.2.6 Phase II Clinical Trial Analysis
  4.2.7 Terminated Trials Analysis
4.3 Dyslipidemia
  4.3.1 Primary Endpoints Used in Dyslipidemia
  4.3.2 Secondary Endpoints Used in Dyslipidemia
  4.3.3 Major Marketed Drugs - Safety and Efficacy Analysis
  4.3.4 Phase III Clinical Trial Analysis
  4.3.5 Most Promising Drug’s Profile
  4.3.6 Phase II Clinical Trial Analysis
  4.3.7 Terminated Trials Analysis
4.4 Hypertension
  4.4.1 Primary Endpoints Used in Hypertension
  4.4.2 Secondary Endpoints Used in Hypertension
  4.4.3 Major Marketed Drugs - Safety and Efficacy Analysis
  4.4.4 Phase III Clinical Trial Analysis
  4.4.5 Most Promising Drug’s Profile
  4.4.6 Phase II Clinical Trial Analysis
  4.4.7 Terminated Trials Analysis
4.5 Venous Thromboembolism
  4.5.1 Primary Endpoints Used in Venous Thromboembolism
  4.5.2 Secondary Endpoints Used in Venous Thromboembolism
  4.5.3 Major Marketed Drugs - Safety and Efficacy Analysis
  4.5.4 Phase III Clinical Trial Analysis
  4.5.5 Most Promising Drug’s Profile
  4.5.6 Phase II Clinical Trial Analysis
  4.5.7 Terminated Trials Analysis

5 ENDPOINTS - CLINICAL TRIALS IN CARDIOVASCULAR DISORDERS - COMPETITIVE LANDSCAPE

5.1 Pfizer Inc.
  5.1.1 Company Overview
  5.1.2 Major Cardiovascular Drugs Marketed by Pfizer
5.2 Sanofi S.A.
  5.2.1 Company Overview
  5.2.2 Major Cardiovascular Drugs Marketed by Sanofi S.A.
5.3 Novartis AG
  5.3.1 Company Overview
  5.3.2 Major Cardiovascular Drugs Marketed by Novartis AG
5.4 AstraZeneca PLC
  5.4.1 Company Overview
  5.4.2 Major Cardiovascular Drugs Marketed by AstraZeneca PLC
5.5 Boehringer Ingelheim GmbH
  5.5.1 Company Overview
  5.5.2 Major Cardiovascular Drugs Marketed by Boehringer Ingelheim GmbH
5.6 Actelion Ltd.
  5.6.1 Company Overview
  5.6.2 Major Cardiovascular Drugs Marketed by Actelion Ltd.
5.7 Daiichi Sankyo Company Ltd.
  5.7.1 Company Overview
  5.7.2 Major Cardiovascular Drugs Marketed by Daiichi Sankyo Company Ltd.
5.8 Abbott Laboratories
  5.8.1 Company Overview
  5.8.2 Major Cardiovascular Drugs Marketed by Abbott Laboratories
5.9 Bayer AG
  5.9.1 Company Overview
  5.9.2 Major Cardiovascular Drugs Marketed by Bayer AG
5.10 GlaxoSmithKline PLC
  5.10.1 Company Overview
  5.10.2 Major Cardiovascular Drugs Marketed by GlaxoSmithKline PLC

6 ENDPOINTS - CLINICAL TRIALS IN CARDIOVASCULAR DISORDERS - APPENDIX

6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
  6.3.1 Coverage
  6.3.2 Secondary Research
  6.3.3 Primary Research
  6.3.4 Section Methodology
  6.3.5 Expert Panel Validation
6.4 Contact Us
6.5 Disclaimer
6.6 Sources

LIST OF TABLES

Table 1: Endpoints - Clinical Trials in Cardiovascular Disorders, Number of Pipeline Products in Phase III Stage of Development, 2011
Table 2: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Endpoints for Major Marketed Drugs, 1990-2010
Table 3: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Endpoints for Major Marketed Drugs, 1990-2010
Table 4: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Endpoints for Major Marketed Drugs, 1990- 2010
Table 5: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Endpoints for Major Marketed Drugs, 1990- 2010
Table 6: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Trial Molecules, 2000-2010
Table 7: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase III Trial Molecules, 2000-2010
Table 8: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase II Trial Molecules, 2000-2010
Table 9: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase II Trial Molecules, 2000-2010
Table 10: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Terminated Trial Molecules, 2000-2010
Table 11: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Trial Molecules, 2000-2010
Table 12: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase III Trial Molecules, 2000-2010
Table 13: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Trial Molecules, 2000-2010
Table 14: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase II Trial Molecules, 2000-2010
Table 15: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Terminated Trial Molecules, 2000-2010
Table 16: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Trial Molecules, 2000-2010
Table 17: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase III Trial Molecules, 2000-2010
Table 18: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase II Trial Molecules, 2000-2010
Table 19: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase II Trial Molecules, 2000-2010
Table 20: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Terminated Trial Molecules, 2000-2010
Table 21: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Completed Phase III Trial Molecules, Global, 2000-2010
Table 22: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase III Trial Molecules, 2000-2010
Table 23: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Trial Molecules, 2000-2010
Table 24: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase II Clinical Trials, Primary Endpoints, 2000-2010
Table 25: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase II Trial Molecules, 2000-2010
Table 26: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Terminated Trial Molecules, 2000-2010
Table 27: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Trial Molecules, 2000-2010
Table 28: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Ongoing Phase III Trial Molecules, 2000-2010
Table 29: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Trial Molecules, Global, 2000-2010
Table 30: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Ongoing Phase II Clinical Trials, Primary Endpoints, Global, 2000-2010
Table 31: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Ongoing Phase II Trial Molecules, Global, 2000-2010
Table 32: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Terminated Trial Molecules, Global, 2000-2010
Table 33: Endpoints - Clinical Trials in Cardiovascular Disorders, Pfizer Inc., Major Cardiovascular Drugs, 2010
Table 34: Endpoints - Clinical Trials in Cardiovascular Disorders, Sanofi S.A., Major Cardiovascular Drugs, 2010
Table 35: Endpoints - Clinical Trials in Cardiovascular Disorders, Novartis AG, Major Cardiovascular Drugs, 2010
Table 36: Endpoints - Clinical Trials in Cardiovascular Disorders, AstraZeneca Plc, Major Cardiovascular Drugs, 2010
Table 37: Endpoints - Clinical Trials in Cardiovascular Disorders Boehringer Ingelheim GmbH, Major Cardiovascular Drugs, 2010
Table 38: Endpoints - Clinical Trials in Cardiovascular Disorders, Actelion Inc., Major Cardiovascular Drugs, 2010
Table 39: Endpoints - Clinical Trials in Cardiovascular Disorders, Daiichi Sankyo Company Ltd., Major Cardiovascular Drugs, 2010
Table 40: Endpoints - Clinical Trials in Cardiovascular Disorders, Abbott Laboratories, Major Cardiovascular Drugs, 2010
Table 41: Endpoints - Clinical Trials in Cardiovascular Disorders, Bayer AG, Major Cardiovascular Drugs, 2010
Table 42: Endpoints - Clinical Trials in Cardiovascular Disorders, GlaxoSmithKline PLC, Major Cardiovascular Drugs, 2010

LIST OF FIGURES

Figure 1: Endpoints - Clinical Trials in Cardiovascular Disorders, Number of Pipeline Products in Phase III Stage of Development, 2011
Figure 2: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 3: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 4: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 5: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 6: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 7: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 8: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 9: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase II Clinical Trials, Primary Endpoints, 2000-2010
Figure 10: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase II Clinical Trials, Secondary Endpoints, 2000-2010
Figure 11: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Completed Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 12: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase II Clinical Trials, Primary Endpoints, 2000-2010
Figure 13: Endpoints - Clinical Trials in Cardiovascular Disorders, Atherosclerosis, Global, Ongoing Phase II Clinical Trials, Secondary Endpoints, 2000-2010
Figure 14: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 15: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 16: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 17: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 18: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 19: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 20: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 21: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Clinical Trials, Primary Endpoints, 2000-2010
Figure 22: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 23: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Clinical Trials, Secondary Endpoints, 2000-2010
Figure 24: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Completed Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 25: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase II Clinical Trials, Primary Endpoints, 2000-2010
Figure 26: Endpoints - Clinical Trials in Cardiovascular Disorders, Atrial Fibrillation, Global, Ongoing Phase II Clinical Trials, Secondary Endpoints, 2000-2010
Figure 27: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 28: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 29: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 30: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 31: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 32: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 33: Endpoints - Clinical Trials in Cardiovascular Disorder, Dyslipidemia, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 34: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase II Clinical Trials, Primary Endpoints, 2000-2010
Figure 35: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 36: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Completed Phase II Clinical Trials, Secondary Endpoints, Global, 2000-2010
Figure 37: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 38: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase II Clinical Trials, Primary Endpoints, 2000-2010
Figure 39: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase II Clinical Trials, Secondary Endpoints, 2000-2010
Figure 40: Endpoints - Clinical Trials in Cardiovascular Disorders, Dyslipidemia, Global, Ongoing Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 41: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 42: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 43: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 44: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 45: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 46: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 47: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 48: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Clinical Trials, Primary Endpoints, 2000-2010
Figure 49: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 50: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Clinical Trials, Secondary Endpoints, 2000-2010
Figure 51: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Completed Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 52: Endpoints - Clinical Trials in Cardiovascular Disorders, Hypertension, Global, Ongoing Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 53: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 54: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Clinical Trials, Classification of Multiple Primary Endpoints, 2000-2010
Figure 55: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 56: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Completed Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 57: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Ongoing Phase III Clinical Trials, Primary Endpoints, 2000-2010
Figure 58: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Ongoing Phase III Clinical Trials, Secondary Endpoints, 2000-2010
Figure 59: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Global, Ongoing Phase III Clinical Trials, Classification of Multiple Secondary Endpoints, 2000-2010
Figure 60: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Clinical Trials, Primary Endpoints, Global, 2000-2010
Figure 61: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Clinical Trials, Classification of Multiple Primary Endpoints, Global, 2000-2010
Figure 62: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Clinical Trials, Secondary Endpoints, Global, 2000-2010
Figure 63: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Completed Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, Global, 2000-2010
Figure 64: Endpoints - Clinical Trials in Cardiovascular Disorders, Venous Thromboembolism, Ongoing Phase II Clinical Trials, Classification of Multiple Secondary Endpoints, Global, 2000-2010

COMPANIES MENTIONED

Pfizer Inc.
Sanofi S.A.
Novartis AG
AstraZeneca PLC
Boehringer Ingelheim GmbH
Actelion Ltd.
Daiichi Sankyo Company Ltd.
Abbott Laboratories
Bayer AG
GlaxoSmithKline PLC

Ask Your Question

Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: